Free Trial

Leap Therapeutics Q4 2022 Earnings Report

Leap Therapeutics logo
$2.79 -0.11 (-3.79%)
(As of 12/3/2024 ET)

Leap Therapeutics EPS Results

Actual EPS
-$1.10
Consensus EPS
-$0.90
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

Leap Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Leap Therapeutics Announcement Details

Quarter
Q4 2022
Time
Q4 2022 Earnings Release
The 2024 TECH RESET (Ad)

Are we on the edge of the biggest ‘TECH RESET’ in decades?

Click here for the step-by-step details

Leap Therapeutics Earnings Headlines

Lock in this disruptor’s share price before 12/5
Spencer Rascoff co-founded Zillow. Austin Allison sold his company to Zillow for $125M. Now they’ve joined forces to launch a venture transforming the $1.3T vacation home market – and the results are already turning heads. This company is leading the co-ownership revolution, offering buyers a chance to own a fraction of a luxury vacation home instead of the entire thing. It’s a model that’s unlocked new demand and earned them over $100M in gross profits in four years.
Leap Therapeutics Reports Q3 2024 Progress and Financials
See More Leap Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Leap Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Leap Therapeutics and other key companies, straight to your email.

About Leap Therapeutics

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

View Leap Therapeutics Profile

More Earnings Resources from MarketBeat